Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Morgan Stanley Reports 5.1% Dolby Laboratories Stake

Morgan Stanley and Atlanta Capital Management Company, LLC filed Amendment No. 6 to Schedule 13G with the SEC on November 13, 2026, disclosing their combined beneficial ownership of Class A Common Stock in Dolby Laboratories, Inc. as of September 30, 2026.

Anjali Anand | 13 November 2026

Zhen Li Reports 9.7% Stake in ADARx Pharmaceuticals

Zhen Li filed a Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of approximately 9.7% of the common stock of ADARx Pharmaceuticals, Inc., as of September 30, 2026.

Shwetambri Chauhan | 13 November 2026

Dayah Energy Partners Reports 193,889 Shares in Ramaco Resources

Dayah Energy Partners, L.P., Dayah Energy GP, LLC, Dayah Capital LLC, and Jonathan Siscovick filed Amendment No. 2 to Schedule 13G with the SEC on November 13, 2026, disclosing a combined beneficial ownership position in Ramaco Resources, Inc. Class A Common Stock as of …

Manish Choudhary | 13 November 2026

AWM Investment Company Discloses 8.9% Kopin Corp Stake

AWM Investment Company, Inc. filed Amendment No. 2 to a Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 17,490,062 shares of Kopin Corp common stock as of September 30, 2026.

Aditi Sarkar | 13 November 2026

GreenLight Ventures Files Amended 13D on Nexalin, Tranche 3 Shares

GreenLight Ventures, LLC filed Amendment No. 1 to its Schedule 13D with the SEC on November 13, 2026, disclosing updated beneficial ownership of common stock in Nexalin Technology, Inc. following the issuance of a third tranche of shares on November 10, 2026.

Nitish Kishor | 13 November 2026

ARCH Venture Discloses 18,486,894 Shares in Prime Medicine

ARCH Venture Management, LLC and affiliated entities filed Amendment No. 3 to Schedule 13D with the SEC on November 13, 2026, reporting beneficial ownership of common stock in Prime Medicine, Inc. as of the triggering event date of November 12, 2026.

Vinay Lochav | 13 November 2026

Autolus Registers 10,653,613 Additional ADS Shares Under 2018 Plan

Autolus Therapeutics plc filed a Form S-8 registration statement with the U.S. Securities and Exchange Commission on November 13, 2026, to register an additional 10,653,613 ordinary shares represented by American Depositary Shares under its 2018 Equity Incentive Plan.

Vinay Lochav | 13 November 2026

Rail Vision Registers 300,000 Shares Under Amended Option Plan

Rail Vision Ltd. filed a Form S-8 registration statement with the U.S. Securities and Exchange Commission on November 13, 2026, to register an additional 300,000 ordinary shares issuable under its Amended Share Option Plan.

Manish Choudhary | 13 November 2026

Lyell Immunopharma Files S-3 to Register 7,428,040 Resale Shares

Lyell Immunopharma, Inc. filed a Form S-3 registration statement with the SEC on November 13, 2026, covering the resale of up to 7,428,040 shares of common stock by selling stockholders who received those shares in a private placement that closed on November 4, 2026.

Vinay Lochav | 13 November 2026

SHF Holdings Faces Nasdaq Delisting After $0.10 Bid Price Breach

SHF Holdings, Inc. filed a current report on Form 8-K on November 13, 2026, disclosing a Nasdaq delisting determination, a waiver extending its registration statement filing deadline, and the issuance of more than 63 million shares of common stock through Series B Preferred Stock …

Aditi Sarkar | 13 November 2026
Support

Hi! How can we help you today?

Loading…